BI 2536
- Generic Name
- BI 2536
- Drug Type
- Small Molecule
- Chemical Formula
- C28H39N7O3
- CAS Number
- 755038-02-9
- Unique Ingredient Identifier
- 4LJG22T9C6
- Background
BI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).
Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT02211859
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT02211833
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 89
- Registration Number
- NCT00710710
- Locations
- 🇩🇪
1216.10.49013 Boehringer Ingelheim Investigational Site, Celle, Germany
🇩🇪1216.10.49007 Boehringer Ingelheim Investigational Site, Essen, Germany
🇦🇹1216.10.43001 Boehringer Ingelheim Investigational Site, Wien, Austria
Phase II Study of BI 2536 in Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT00706498
- Locations
- 🇬🇧
1216.19.4405 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom
🇬🇧1216.19.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1216.19.4407 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT00701766
- Locations
- 🇩🇪
1216.20.49007 Boehringer Ingelheim Investigational Site, Heidelberg, Germany
🇦🇹1216.20.43002 Boehringer Ingelheim Investigational Site, Wien, Austria
🇩🇪1216.20.49002 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
- Conditions
- Endometrial CancerHead and Neck CancerMelanoma (Skin)Breast CancerOvarian CancerSarcoma
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2013-10-07
- Target Recruit Count
- 76
- Registration Number
- NCT00526149
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
BI 2536 Second Line Monotherapy in SCLC
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT00412880
- Locations
- 🇺🇸
1216.11.003 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸1216.11.006 Boehringer Ingelheim Investigational Site, Evanston, Illinois, United States
🇨🇦1216.11.009 Alberta Cancer Board, Edmonton, Alberta, Canada
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00376623
- Locations
- 🇩🇪
1216.9.49001 Boehringer Ingelheim Investigational Site, Heidelberg, Germany
🇩🇪1216.9.49002 Boehringer Ingelheim Investigational Site, Freiburg, Germany
🇩🇪1216.9.49007 Boehringer Ingelheim Investigational Site, Gauting, Germany
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Lymphoma
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00243087
- Locations
- 🇺🇸
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.